drugset / Trial / NCT00557973
A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury
RandomizedCrossoverQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate efficacy and safety of treatment with XP19986 Sustained Release (SR) Tablet compared to placebo in subjects with spasticity due to spinal cord injury
Timeline
- Start
- 2007-12
- Primary completion
- 2009-04
- Completion
- 2009-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Arbaclofen Placarbil | Small molecule | 10 mg | Oral |
| Subject | Arbaclofen Placarbil | Small molecule | 20 mg | Oral |
| Subject | Arbaclofen Placarbil | Small molecule | 30 mg | Oral |
Indications
No indication recorded.